Monoamine oxidase type B inhibitors (MAOBIs), such as selegiline, may be beneficial in patients with early Parkinson's disease. In a meta-analysis including 17 trials and 3525 patients, Ives and colleagues (p 593) found that patients taking MAOBIs had better total scores, motor scores, and activities of daily living scores on the unified Parkinson's disease rating scale at three months than patients taking placebo; they were also less likely to need additional levodopa or to develop motor fluctuations, and they were not more likely to die or experience side effects.
